Inflammatory cytokines, cognition, and response to antidepressant treatment in patients with major depressive disorder

被引:10
|
作者
Zhou, Qi [1 ,2 ]
Lv, Xiaozhen [1 ,2 ]
Zhou, Shuzhe [1 ,2 ]
Liu, Qi [1 ,2 ]
Tian, Hongjun [3 ]
Zhang, Kerang [4 ]
Wei, Jing [5 ]
Wang, Gang [6 ]
Chen, Qiaoling [7 ]
Zhu, Gang [8 ]
Wang, Xueyi [9 ]
An, Cuixia [9 ]
Zhang, Nan [10 ]
Huang, Yu [11 ]
Si, Tianmei [1 ,2 ]
Yu, Xin [1 ,2 ]
Shi, Chuan [1 ,2 ]
机构
[1] Peking Univ Sixth Hosp, Peking Univ Inst Mental Hlth, Beijing, Peoples R China
[2] Peking Univ, NHC Key Lab Mental Hlth, Natl Clin Res Ctr Mental Disorders, Peking Univ Sixth Hosp, Beijing, Peoples R China
[3] Nankai Univ, Affiliated Anding Hosp, Tianjin Mental Hlth Ctr, Tianjin, Peoples R China
[4] Shanxi Med Univ, Dept Psychiat, First Hosp, Taiyuan, Shanxi, Peoples R China
[5] Peking Union Med Coll Hosp, Dept Psychol Med, Beijing, Peoples R China
[6] Capital Med Univ, Beijing Anding Hosp, Beijing, Peoples R China
[7] Dalian Seventh Peoples Hosp, Dept Psychiat, Dalian, Peoples R China
[8] China Med Univ, Dept Psychiat, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China
[9] Hebei Med Univ, Dept Psychiat, First Hosp, Mental Hlth Inst, Shijiazhuang, Hebei, Peoples R China
[10] Tianjin Med Univ Gen Hosp, Dept Neurol, Tianjin, Peoples R China
[11] Peking Univ, Natl Engn Res Ctr Software Engn, Beijing, Peoples R China
基金
国家重点研发计划;
关键词
Major depressive disorder; Cognition; Inflammatory cytokines; Treatment response; GENE-EXPRESSION; SYMPTOMS; DEFICITS; MYELOPEROXIDASE; INTERLEUKIN-6; RELIABILITY; SENSITIVITY; PERFORMANCE; IMPAIRMENT; MARKERS;
D O I
10.1016/j.psychres.2021.114202
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Inflammation and cognition are related to major depressive disorder (MDD), but the role in treatment response remains unclear. In this study, we investigated correlation between inflammatory cytokines and cognition in MDD patients treated with antidepressant medication. Methods: The participants were 149 MDD patients. Cytokines before therapy, cognitive assessments and severity of depression before and after therapy were tested. Logistic regression was used to explore underlying risks treatment response. Results: There were significant differences in smoking, alcohol drinking, and Stroop Color Test(SCT), Stroop Color-Word Test (SCWT), and Continuous Performance Test(CPT) scores between response group (RG) and nonresponse group (NRG) at baseline. Performance of patients in RG improved more in Brief Assessment of Cognition in Schizophrenia (BACS), Color Trial Test-I (CTT-I), SCT and SCWT after treatment. Levels of baseline IL-18 were associated with baseline learning and memory, and executive function. Treatment response was associated with drinking, performance of CPT and SCT. Conclusion: MDD patients with different treatment responses have different cognitive defects, especially in speed of processing and executive function. Expression of cytokines is associated with cognition and may influence treatment response. Better speed of processing and executive function, and poorer attention at baseline may respond better to antidepressant treatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Neural Correlates of Antidepressant Treatment Response in Adolescents with Major Depressive Disorder
    Cullen, Kathryn R.
    Klimes-Dougan, Bonnie
    Dung Pham Vu
    Schreiner, Melinda Westlund
    Mueller, Bryon A.
    Eberly, Lynn E.
    Camchong, Jazmin
    Westervelt, Ana
    Lim, Kelvin O.
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2016, 26 (08) : 705 - 712
  • [12] The inflammatory cytokines: molecular biomarkers for major depressive disorder?
    Martin, Charlotte
    Tansey, Katherine E.
    Schalkwyk, Leonard C.
    Powell, Timothy R.
    [J]. BIOMARKERS IN MEDICINE, 2015, 9 (02) : 169 - 180
  • [13] Association of Inflammatory Genes in Treatment Response in Major Depressive Disorder
    Portella, Maria
    Glahn, David
    Whalley, Heather
    Sprooten, Emma
    Knowles, Emma
    [J]. BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S19 - S19
  • [14] Rumination in patients with major depressive disorder before and after antidepressant treatment
    Segerberg, T.
    Ozenne, B.
    Dam, V. H.
    Kohler-Forsberg, K.
    Jorgensen, M. B.
    Frokjaer, V. G.
    Knudsen, G. M.
    Stenbaek, D. S.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S530 - S530
  • [15] Rumination in patients with major depressive disorder before and after antidepressant treatment
    Segerberg, Tina S. S.
    Ozenne, Brice
    Dam, Vibeke H.
    Kohler-Forsberg, Kristin
    Jorgensen, Martin B.
    Frokjaer, Vibe G.
    Knudsen, Gitte M.
    Stenbaek, Dea S.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2024, 360 : 322 - 325
  • [16] The effect of antidepressant treatment on quality of life in patients with major depressive disorder
    Aydemir, O.
    Ergun, H.
    Kesebir, S.
    Soygur, H.
    Tulunay, C. F.
    [J]. BIPOLAR DISORDERS, 2010, 12 : 5 - 5
  • [17] Antidepressant medication treatment patterns in Asian patients with major depressive disorder
    Novick, Diego
    Montgomery, William
    Moneta, Victoria
    Peng, Xiaomei
    Brugnoli, Roberto
    Haro, Josep Maria
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 421 - 428
  • [18] Neural Markers of Early Treatment Response During Antidepressant Treatment in Major Depressive Disorder
    Ramasubbu, Rajamannar
    Goodyear, Bradley
    Gaxiola, Ismael
    MacQueen, Glenda
    [J]. BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 145S - 145S
  • [19] The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder
    Caudill, Marissa M.
    Hunter, Aimee M.
    Cook, Ian A.
    Leuchter, Andrew F.
    [J]. CLINICAL EEG AND NEUROSCIENCE, 2015, 46 (04) : 277 - 284
  • [20] ANTIDEPRESSANT RESPONSE IN MAJOR DEPRESSIVE DISORDER AND RARE VARIANTS
    Wong, Ma-Li
    Arcos-Burgos, Mauricio
    Licinio, Julio
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : 1304 - 1304